Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.40 USD
-0.07 (-4.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGTX 1.40 -0.07(-4.76%)
Will CGTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
50 Day Moving Average Resistance appears for CGTX after 4.76% move
CGTX Fell Below 50 Day Moving Average on September 19
Is CGTX primed for upward momentum? 50 Day Moving Average Support shows up after crashing 8.7%
Non-ADX 1,2,3,4 Bullish appears for CGTX after 4.55% move
Is CGTX heading for a slide? New Downtrend shows up after plummeting 29.03%